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World Health Organization and the United States Center for Disease Control have recently recommended the use of 0.8 FIO2 in all adult 
surgical patients undergoing general anaesthesia, to prevent surgical site infections. This recommendation has arisen several discus-
sions: As a matter of fact, there are numerous studies with different results about the effect of FIO2 on surgical site infection. Moreover, 
the clinical effects of FIO2 are not limited to infection control.
We asked some prominent authors about their comments regarding the recent recommendations
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Introduction
Joseph Priestley, (one of ) the discoverer(s) of oxygen, has quoted: “… though pure dephlogistated air might be very useful as a med-
icine, it might not be so proper for us in the usual healthy state of the body; for, as a candle burns out much faster in dephlogistated 
than in common air, so we might live out too fast, and the animal powers be too soon exhausted in the pure king of air. A moralist 
would say that the air which nature has provided for us is as good as we deserve…”.
Members of the WHO Guidelines Development Group recently attempted to provide worldwide “evidence-based recommendations” 
for the prevention of surgical site infections (SSI) by stating: “Adult patients undergoing general anaesthesia with endotracheal in-
tubation for surgical procedures should receive 80% fraction of inspired oxygen intraoperatively and, if feasible, in the immediate 
postoperative period for 2–6 h”. 
Pro’s & Con’s of different levels of FIO2 during the intraoperative (and somehow “peri”operative) period have been a very hot topic 
in our discipline. However, whether there is any obvious rule in terms of “evidence-based medicine”, is hard to claim. 
We asked some prominent authors about their comments regarding the recent recommendation. Although this text is based on “ex-
pert-opinion”s, the reader has to take in account that the authors of this text are the ones who have published the majority of high-im-
pact studies, which obtained/lead to the “evidence” in this topic. 
The contributions are in alphabetical order regarding the surnames of the authors. 
Mert Şentürk
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Ozan Akca: 
Who needs high FIO2? Question is simple and the answer is 
easy. Hypoxic patient needs oxygen. 
How can we deliver that needed oxygen? Oxygen delivery 
(DO2) depends on two things: cardiac output (CO) and arte-
rial oxygen content (CaO2). 
DO2 = CO x CaO2 
Although the equation relies on pump function and a good 
level of hemoglobin (as the main oxygen carrier), tissue oxygen 
delivery is influenced by many other factors, first one being 
FIO2, highlighting importance of free oxygen (1, 2). Incre-
mental FIO2 increases arterial oxygen tensions, which results in 
higher tissue oxygen delivery linearly within the clinical range 
(2). Additionally, hypothermia-related vasoconstriction (3), 
pain-related sympathetic response,(4) intravascular volume 
status, (2, 5) and carbon dioxide partial pressures (6) also alter 
tissue oxygenation. The latter factors mechanistically mostly 
rely more on local-regional tissue perfusion. 
Now, let’s get back to the question: “WHO needs high 
FIO2?”. In fact, the question appears to criticize the World 
Health Organization’s (WHO) global guidelines for surgical 
site infection (SSI) prevention (7). WHO’s recommendation 
says that adult patients undergoing general endotracheal an-
esthesia to receive FIO2 of 0.80 intraoperatively and -if fea-
sible- in the immediate postoperative period for 2-6 hours. 
Category was ranked as “strong”, and the evidence level was 
marked as “moderate quality”. 
Recently, the Centers for Disease Control (CDC) published 
their guidelines for prevention of SSI (8). CDC acknowl-
edged other organizations’ recommendations, and came up 
with a slightly different approach. Although they did not 
recommend an optimal level, duration, and delivery method 
of FIO2 for SSI prevention, they suggested administration 
of increased FIO2 intra-operatively and in the immediate 
postoperative period for patients with normal pulmonary 
function undergoing general anesthesia. They added the 
maintenance of perioperative normothermia and adequate 
volume replacement as required items for optimum tissue 
oxygen delivery (Category IA–strong recommendation; 
moderate-quality evidence.). These additional requirements 
partially address what I mentioned above for better tissue 
oxygen delivery. 
At this point, one may think that during the preparation 
of these guidelines, neither WHO nor CDC took the time 
the dig into the Oxygen Controversy or had the most recent 
meta-analysis (9) to influence their recommendations. Sta-
tistically, it’s hard to ignore the controversy of supplemen-
tal oxygen / high FIO2 use and SSI, but instead of focusing 
on the details of these analyses, I suggest understanding the 
methodological differences between the so-called controver-
sial data (1, 10). There are many unanswered questions in 
spite of published large trials presenting thousands of pa-
tients’ data, years of scientific effort, and millions of research 
dollars invested: 
- Why and when one may need high FIO2 perioperatively?
- What is the normal level of oxygenation of surgical tis-
sues and organs-of-interest and how can we maintain 
those normals?
- How can we deliver high FIO2 to the tissues-of-interest? 
Is it easy?
- and finally, if we can deliver that required oxygen to the 
tissue, can we expect better surgical outcomes?
Now, back to Joseph Priestley: “…though pure dephlogistated 
air might be very useful as a medicine, it might not be so proper 
for us in the usual healthy state of the body…”. True statement, 
but can we really summarize the “perioperative abdominal 
surgery in a high risk patient” as “healthy state of the body”? 
One would also wonder what Priestley knew about “surgical 
stress”. Answers are “no” and “not much”, respectively; oth-
erwise the whole field of “perioperative medicine” would be 
obsolete. 
About 50 years ago, Dr. Thomas Hunt managed to mea-
sure tissue oxygen tensions and started researching impor-
tance of oxygenation in the experimental surgical setting 
(11-13). Some years later, Drs. Hunt and Hopf established 
a landmark perioperative physiology, and reported tissue 
oxygen tension as the main predictor of surgical wound 
infections (14). When subcutaneous tissue oxygen tensions 
stay above 60-80mmHg -which happens when PaO2>300 
mmHg (2) SSI happens less frequently than expected. So, 
it’s very likely that in most of the recent high FIO2 and 
SSI outcomes studies, provided supplemental oxygen was 
not delivered sufficiently to the tissues, because their re-
ported PaO2 levels were not that high (10, 15-17). In fact, 
until now, there has been only one study where we know 
that optimum level of oxygen delivered to tissue (i.e. tissue 
PO2>60 mmHg), (1) and that’s still the only study, where 
we showed when high FIO2 delivered to tissue, SSI was 
prevented (1). If oxygen is not even delivered, how can we 
expect it to protect the tissue of concern? 
In summary: first, the very question is a valid question, “who 
needs high FIO2?”. Second, the very first hypothesis “main-
tenance of tissue oxygenation improves surgical outcomes” is still 
open and desperately needs to be further studied, possibly 
even beyond the context of high FIO2. …And third…inter-
preting evidence is harder than it looks and it can even be 
tricky for global institutes.
* * *
Lorenzo Ball and Paolo Pelosi: 
It is our opinion that answering this question is rather easy: 
high FIO2 should be used in patients that are in need for it, 
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namely those in which lower oxygen delivery fails to main-
tain oxygenation within safety margins. In the operating 
room, guidelines recommend to target oxygenation to a pe-
ripheral oxygen saturation (SpO2) ≥ 92%, (18) nonetheless 
a recent large observational study reported that most sur-
gical patients receive FIO2 between 0.4 and 0.8, resulting 
in saturation values ≥ 96% in nearly all cases (19). Based 
on this report, one could conclude that most of the surgi-
cal patients already receive ‘high’ FIO2, possibly resulting 
in supra-physiological oxygenation. Over the last decades, 
several authors have investigated the effects of hyperoxia, 
achieved with the deliberate administration of higher FIO2, 
to improve the efficiency of neutrophil oxidative burst at the 
surgical wound site and to reduce the incidence of SSIs (20). 
However, studies investigating the use of different FIO2 lev-
els should comprise several end-points, to reflect the com-
plexity of the effects of oxygen on different organs’ function. 
The guidelines recently published on behalf of the WHO 
Guidelines Development Group, (21) recommend the use of 
0.8 FIO2 in the whole intra- and post-operative period in all 
surgical patients to reduce the incidence of SSIs. This rec-
ommendation, that the WHO grades as ‘strong’ and based 
on ‘moderate’ evidence quality, received criticisms from re-
searchers in anaesthesiology (22, 23). In fact, the studies in-
cluded in the meta-analysis on which the recommendation 
is based are heterogeneous in design and aims, include stud-
ies with potentially clamorous confounding factors such as 
the use of inhaled nitrous oxide (24). A much more com-
plete Cochrane review of the literature, published one year 
before the WHO guideline, concluded that evidence does 
not support the routine use of FIO2 higher than 0.6 during 
anaesthesia and surgery, while the risk of adverse events 
including mortality could even be increased with higher 
versus lower FIO2 (25). A partial exception could be rep-
resented by the induction phase, when higher FIO2 could 
allow a longer time to perform the intubation manoeuvre, 
which could be crucial in unexpected difficult intubation 
or in the uncommon but life-threatening ‘can’t-ventilate, 
can’t-intubate’ scenario (26). Nonetheless, also at induction 
higher FIO2 could have detrimental effects, therefore during 
pre-oxygenation FIO2 higher than 0.7-0.8 should be avoid-
ed, and positive-pressure non-invasive ventilation (NPPV) 
could be considered in selected cases. The WHO guideline 
extends the recommendation of administering high FIO2 
also in the post-operative period. It is our opinion that, also 
in this case, oxygen administration should be based on clin-
ical need and pathophysiological reasoning rather than on 
a routine basis. Post-operative de-saturation is a common 
complication, that could be secondary to the development 
of postoperative atelectasis or several other mechanisms (18, 
27). Recently, an easy method has been proposed to surgical 
patients for postoperative atelectasis, consisting in measur-
ing the SpO2 during a 5-minutes room air breathing test: a 
SpO2 ≤96% had a high sensitivity and specificity for atelec-
tasis (28). Based on this test, the clinician could opt for the 
most appropriate treatment, including oxygen administra-
tion and FIO2 titration or NPPV. 
* * *
F. Javier Belda, Carlos Ferrando, Marina Soro: 
In line with recent guidelines, we do recommend perioper-
ative FIO2 of 80% in major abdominal surgery because of 
several reasons:
1. No anesthesiologist doubts that there are circumstances 
where short periods of hyperoxia may actually increase pa-
tient safety, e.g. during the induction of anaesthesia and for 
intubation in ICU patients to delay the onset of hypoxemia 
during apnea (29). In fact, various maneuvers have been pro-
posed to extend the effect of preoxygenation, including the 
use of high-flow nasal oxygen (30-32).
2. Several meta-analysis have shown that the administra-
tion of high FIO2 (0.8) compared to lower (0.3) seems to 
reduce surgical site infection (33). The effect might be due 
to an increase in partial pressure of tissue oxygen PtsO2 
because an increase in partial pressure of arterial oxygen 
(PaO2), which in turn increases the bacterycidal capacity of 
neutrophils and reduces local oxydative stress as we have 
recently shown (34, 35).
A recent meta-analysis (36) which gathered more than 7000 
patients showed a favourable effect of high FIO2 only in the 
sensitivity analysis but at the same time it showed a very sig-
nifficant effect in the subgroup of patients undergoing col-
orectal surgery (RR: 0.53; 95% CI: 0.37-0.74; p=0.0003). 
The last meta-analysis stil insist in the beneficial effect on SSI 
in colorectal surgery in spite of the lack of clear effect in other 
types of surgery (37). New evidence of the beneficial effect are 
continuously published (38). 
3. The use of supplemental oxygen is widespread in cardiac 
surgery patients, during and after cardiopulmonary bypass. 
Its protective effects with this strategy on the myocardium 
have been reviewed elsewhere (39). However, in a recent 
prospective trial during cardiac surgery a lower FIO2 had no 
worse outcomes when compared to the higher concentrations 
that are commonly used in this setting (40). Finally, in a co-
hort of 83.000 patients after cardiac surgery, no association of 
hyperoxia with mortality was found (41).
4. What is mostly clear is that this perioperative high FIO2 
have no adverse effect. This has been shown in most of the 
studies (and in the referred meta-analysis). For example, the 
PROXI study, the most important study against FIO2 80% 
did not find differences in the incidence of atelectasis, pneu-
monia, respiratory failure or death (10). This may be hypo-
thetically due the use of a FIO2 up to 0.8 for shorts periods of 
time does not increases the production of free radicals when 
used within a lung protective strategy. 
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5. Finally, without bibliographic references, it is clear that the 
WHO cannot recommend harmful things. We feel that the 
WHOGD Group (authors of the guidelines (21)) as the rest 
of physicians in the world, do follow strictly the non-ma-
leficence ethical principle included in the Hippocratic Oath 
“first do not harm”. Although they may accept that high FIO2 
cannot be beneficial for all type of surgeries, they underline 
its sound physiological mechanism that may be beneficial for 
subgroups, together with the high safety demonstrated for 
high FIO2 for this short perioperative period.
From our point of view, two main issues must be underlined:
1. Readers need to detect and reject biased information. It is 
a pity that recognized forums (Cochrane database) have pub-
lished very biased information regarding this issue most likely 
because of the authors' own bias (25). Just an example; in the 
author´s conclusions of Cochrane review is stated that high 
FIO2 may increase long term mortality and this is based on 
a single study (42) that has been recently refused in a much 
higher population (43).
2. Researchers should promote new studies of high quality. 
However, these studies do not have to be undertaken be-
fore solving what is the best strategy for managing the lung 
perioperatively. Perioperative effects of FIO2 can only be dis-
closed in a study where an optimized ventilation strategy is 
applied before, during and after operation. We have started a 
multicentre study on this issue that will show the real effect 
of high FIO2 in the perioperative period.
In summary, we feel that the WHO has just outlined that 
high FIO2 during anesthesia may have many potential bene-
fits, without any inportant adverse effects. Well done!
* * *
Peter Biro: 
The bitter truth is, that my conversion was not caused by ra-
tional reasoning and becoming convinced by evidence-based 
information; the routine use of 80% oxygen in adults has 
simply been directed by the department’s director a decade 
ago. So the only virtue I can claim in this respect is that I was 
a polite follower to higher orders and only later became con-
vinced about the rightfulness of this change. Those of us, who 
have learned and began to practice anesthesia in the eight-
ies, were taught to apply rather low oxygen concentrations 
during anesthesia, mostly around 30%. The arguments of 
our teachers were fourfold. 1) The lower the oxygen concen-
tration is set, the more nitrous oxide we can administer and 
the latter is a weak agent that should be given as highly con-
centrated as possible. 2) High oxygen concentrations might 
produce more so called “resorption atelectasis”. 3) Longer 
lasting respiration or ventilation with high oxygen concen-
trations might degrade surfactant and be therefore harmful 
to the lungs; some even speak of “oxygen toxicity”. Finally 
4) man anyway is used to the atmospheric concentration of 
21% and can live well with it, even in higher altitudes. Be-
sides, we then already knew that newborn babies and young 
infants might even become blind if treated with too much 
oxygen, although it was never clear to us where the critical 
thresholds for oxygen concentration and the child’s age was 
to be located. In the retrospect and guided by more recent 
knowledge and experience, one has to view the old statements 
with some scepticism. The argument favouring nitrous oxide 
delivery that should not be limited by the competing oxygen 
can be viewed as obsolete, since nitrous oxide in most plac-
es faded away from cylinders and supply systems to history 
books. The “resorption atelectasis” argument is to a certain 
extent justified, since it is true that in contrast to the ambient 
air’s nitrogen, oxygen is easily and fast resorbed, thus leav-
ing less volume to expand alveoli (44). However, this static 
view on the issue might be contradicted by positive pressure 
ventilation, which may counterbalance alveolar collapse. That 
oxygen toxicity exists as a medical problem has been recog-
nized in multiple settings. Damages on the central nervous 
system toxicity may be caused by exposure to high oxygen 
partial pressures (as in hyperbaric oxygenation) (45), while 
pulmonary and ocular toxicity may be caused by longer ex-
posure to high oxygen levels at atmospheric pressure condi-
tions (46). However, these conditions might not be present 
in usual anesthesia ventilation with 80% oxygen concentra-
tion. Therefore, the toxicity issue can be put aside, at least 
in patients with otherwise healthy lungs. The final argument 
for a low oxygen concentration that under normal conditions 
the humans can live well with far less oxygen seems to be a 
bit of the tough guy admiration kind. Artificial ventilation 
in supine position is anything else than something normal 
or physiologic, so this view might fit for navy seals but not 
for more or less sick people undergoing surgery. The proven 
effect on suppression of postoperative infections supports the 
80% proponents, in particular in cases of existing or possi-
ble contamination during specific surgical interventions. This 
is even more relevant in patients with a decreased immune 
competence. For these reasons, I vote “yes” for the routine use 
of 80% oxygen during anesthesia ventilation of adults.
* * *
Andrea Cortegiani and Cesare Gregoretti: 
Supplemental or “extra” oxygen is one of the most widely 
used therapies for people admitted to the hospital (47). The 
importance of oxygen therapy for many patients with heart 
and chronic lung diseases is universally recognized (48). Very 
recently the Members of the WHO Guidelines Development 
Group recommend that adult intubated patients undergoing 
general anesthesia for surgical procedures should receive an 
80% fraction of inspired oxygen (FIO2) intraoperatively and, 
if feasible, in the immediate postoperative period for 2–6 h, 
to reduce the risk of surgical site infection (SSI) (21). They 
produced this statement after performing a systematic review 
and meta-analysis including 11 randomized controlled trials 
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comparing perioperative administration of 80% FIO2 com-
pared to 30-35% FIO2. There was moderate grade evidence 
that hyperoxia significantly reduced SSI (OR 0.72, 95% CI 
0.55-0.94). However, we believe that some other aspects of 
oxygen supplementation should be taken into account apart 
from its effect on SSI. 
Since the first case in which oxygen was actually employed as 
remedy, in 1783 as reported by Caillens, what is important 
in term of oxygenation is a never ended story. As a matter 
of fact, most guidelines do not yet recommend dose titra-
tion to accomplish normoxaemia as assessed by invasively or 
noninvasively obtained end-points such as the level of oxygen 
and carbon dioxide (47). Moreover, the effects of oxygen lev-
el may vary widely according to metrics used and exposure 
time (49). Hyperoxia causes complex effects on several phys-
iologic functions. It may affect alveolar ventilation/perfusion 
(Va/Q) (50), may reverse hypoxic vasoconstriction (51, 52), 
may induce pulmonary toxicity (53, 54) and it may reduce 
tissue blood flow due to vasoconstriction (55). Although a 
high partial pressure of oxygen in the blood achieved through 
the administration of high-concentration oxygen may reduce 
cytokine production by leukocytes (56), it can also produce 
structural changes within alveolar macrophages, with an im-
pairment of their antimicrobial activity and a reduction in the 
production of inflammatory cytokines in response to stimula-
tion (57). On the other hand, it may produce a time-depen-
dent pro-inflammatory pulmonary response (58). There is a 
growing body of evidence questioning the effect of hyperoxia 
in many critical care settings; in some cases, there is evidence 
of harmful effects (e.g. post-resuscitation care, acute coronary 
syndrome) whereas in others the effect is controversial (trau-
matic brain injury, sepsis) (59-61). Interestingly, many trials 
addressing the effect of hyperoxia are still ongoing (61).
Regarding in general critically ill patients, there is also evidence 
of harm. A large observational cohort study enrolling 14.441 
patients showed a higher mortality and fewer ventilators free 
days associated with increasing arterial PaO2 and exposure time 
(49). Girardis and colleagues have recently addressed the effect 
of oxygen supplementation, in comparison to a conservative 
protocol, in a randomized trial enrolling 480 critically ill pa-
tients admitted to a single intensive care unit (62). There was 
a significant difference in mortality (relative risk 0.57 [95% 
CI, 0.37-0.90]), less shock episodes, liver failure, and new 
blood-stream infection. However, it was a single-center study 
stopped after the enrollment of approximately two-thirds of 
the planned sample due to slow recruitment.
We believe that, although the data on favorable effects of the 
use of high FIO2 during and after general anesthesia in terms 
of SSI are solid, its widespread use may lead to underesti-
mate the side effects of hyperoxia on organs and physiological 
functions. As for many other decisions in Anesthesiology, a 
“case-by-case” approach seems to be the best option for FIO2 
selection.
Arieh Eden and Zeev Goldik: 
At present there are conflicting recommendations for the use 
of high concentration oxygen therapy during the perioperative 
period for the prevention of surgical site infections. While the 
WHO guidelines recommend the use of this therapy based on 
analysis of current data (21) a recently published Cochrane 
analysis failed to show any benefit from this treatment (25). 
The biological basis for the use of high concentration of ox-
ygen for the prevention of wound infection is that hyperoxia 
enhances oxidative killing by neutrophils. On the other hand, 
it has been shown that hyperoxia is associated with increased 
mortality in various groups of critically ill patients, proba-
bly due to increased oxidative stress (63). The PROXI study, 
which evaluated perioperative high concentration of oxygen 
in more than 1000 patients found a slight decrease in surgical 
wound infection (10). This smaller effect in the prevention of 
wound infection compared to other similar studies could be 
partially explained by the shorter duration of the interven-
tion (two hours of post-operative high oxygen concentration 
compared to six in several other studies). However, further 
analysis revealed that the risk for acute coronary syndrome 
and myocardial infarction was twice as high in the high oxy-
gen group (64), and even more disturbingly, that long-term 
follow-up of (evaluated in over 99% of the initial cohort) 
3.9 years (median) revealed an increase in mortality of nearly 
30%, as well as reduced cancer free survival (65).
In the light of this literature it appears unjustified to recom-
mend the use of high inspiratory oxygen concentration in the 
perioperative period until a large scale long term study is per-
formed to evaluate the safety and efficacy of this treatment. 
* * *
Luciano Gattinoni:
Members of the WHO Guidelines Development Group 
strongly recommended the perioperative administration of 
80% oxygen to prevent infections of the surgical site. The 
biological rationale of such intervention is that the neutro-
phils use the oxidative killing as a primary weapon against 
bacteria, and that several years ago it has been shown that 
the risk of wound infection was inversely proportioned to the 
tissue oxygenation. More precisely, Hopf et al. (14) related 
the increased risk of infection to the lower subcutaneous pO2 
(14). The jump from the biological observations to the oxy-
gen supplementation in clinical practice was almost imme-
diate and led to several randomized trials testing higher vs 
lower FIO2 during anesthesia. The members of WHO chose 
some of these trials to bolster their strong recommendation, 
omitting, however, other trials showing the lack of benefit of 
supplemental oxygen. Volk et al. carefully reviewed this issue 
by reanalyzing in details the available evidence (9). Their con-
clusion was that the WHO recommendation of 80% periop-
erative oxygen is poorly justified.
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Actually, the variability of the results observed during these 
trials is likely due to the fact that what matters is not the ar-
terial oxygen tension, which clearly increases with FIO2, but 
the tissue oxygen tension, which depends not only on the 
arterial oxygen tension, but also on perfusion and on the oxy-
gen consumption. These factors may largely vary in different 
tissues, at different temperature, pH, microcirculation, etc. 
That supplemental oxygen is just a tool to improve neutro-
phils efficiency appears a rather naive vision of the problem. 
Indeed, supplemental oxygen beside theoretically improving 
the neutrophils oxidative capability, affects the whole body. In 
the lung it has been observed decreased mucociliar transport, 
inflammatory reaction, focal pulmonary edema, interstitial 
fibrosis and reabsorption atelectasis. In the cardiocirculatory 
system, higher oxygen tension decreases cardiac output and 
stroke volume with increased peripheral vascular resistances 
and coronary artery vasoconstriction (66-69). The peripheral 
vasoconstriction, in particular, may explain the possible gap 
between high PaO2 and low tissue oxygen tension. 
Therefore, the putative benefit of 80% FIO2 on decreasing 
the risk of wound infection has to be balanced with the neg-
ative effects of the overall increased oxidative stress (70). If, 
as the simplest approach, we list the advantages of increased 
PaO2 in normal men with the disadvantages of high FIO2 on 
lung tissue and of high PaO2 in the whole body system, the 
recommendation of WHO appears highly questionable. Be-
fore blindly adopting it, risks and benefits of high FIO2 must 
be carefully evaluated and balanced.
* * *
Thomas Hachenberg: 
The guidelines recently published by the World Health Or-
ganization (21) and the United States Center for Disease Con-
trol (8) recommend the use of 0.8 FIO2 in all adult surgical 
patients undergoing general anaesthesia. The rationale for 
80% inspired oxygen intraoperatively and also for 2 to 6 
hours postoperatively is to decrease the risk of surgical site 
infection (SSI). For several reasons this recommendation is 
poorly substantiated and one would caution against unjus-
tified implementation into clinical practice. The guidelines 
are based on a meta-analysis including very heterogeneous 
studies, which is a weak scientific and statistical approach. 
Meta-analysis should not serve as a substitute of prospective 
randomized double blind trials with clearly defined end-
points and sufficient sample size. In fact a recent analysis has 
demonstrated that subsequent randomized trials could not 
confirm the conclusions of a majority of earlier meta-anal-
ysis studies (71). Ironically the WHO and CDC guidelines 
rely on a meta-analysis after large clinical trials have failed 
to demonstrate an advantageous effect of perioperative 80% 
oxygen (10, 17). One may also ask whether studies published 
in 2000 or earlier reflect present clinical practice, particularly 
in colorectal or thoracic surgery. More importantly different 
patient groups were not included into many of these stud-
ies due to predefined exclusion criteria. For example patients 
with advanced peripheral arterial occlusion disease, chronic 
obstructive lung disease GOLD IV or congestive heart failure 
NYHA class IV were not included into any of the FIO2 trials, 
however these patients are by no means excluded from anaes-
thesia and surgery in clinical practice. It is unclear whether 
these patients benefit from supplemental oxygen or whether 
the risk of postoperative complications unrelated to SSI is 
actually increased.
I am also concerned that potentially harmful effects of oxy-
gen have not been sufficiently addressed in the WHO and 
CDC guidelines, although data from different clinical stud-
ies suggest that hyperoxia may have detrimental effects. For 
example supplemental oxygen has been considered as stan-
dard therapy for all patients who present with acute coronary 
syndrome, regardless of arterial oxyhaemoglobin saturation 
(SpO2) (72). Likewise oxygen treatment has been used after 
ischaemic stroke, cardiac arrest, in septic patients or traumat-
ic brain injury. However the efficacy of supranormal PaO2 in 
patients with acute myocardial infarction is questionable. In 
a prospective randomised study supplemental oxygen ther-
apy in patients with ST-elevation-myocardial infarction but 
without hypoxia was associated with an elevated mean peak 
creatine kinase and larger myocardial infarct size assessed at 
6 months (60). In cardiac surgical patients intraoperative hy-
peroxia was associated with an increased prevalence of post-
operative delirium, suggesting that supranormal PaO2 may 
have adverse cerebral effects (73). A retrospective study on 
adult patients with nontraumatic cardiac arrest (n=6.326) 
and cardiopulmonary resuscitation within 24 hours prior to 
ICU arrival found that 18% presented with hyperoxia, 19% 
with normoxia and 63% with hypoxia. The hyperoxia group 
had significantly higher in-hospital mortality compared with 
the normoxia group and the hypoxia group (74). Although 
the role of oxygen on outcome is still unclear after resusci-
tation the data may indicate that hyperoxia per se is not as 
harmless as previously thought. Concerns about unjusti-
fied use of an increased FIO2 are supported by preliminary 
data from a single-centre study suggesting that in critically 
ill patients a PaO2 between 70 and 100 mmHg or arterial 
oxyhaemoglobin saturation (SpO2) between 94% and 98% 
was associated with lower ICU mortality (62). In summary 
different specialties modify their clinical practice in favour of 
normoxia rather than of hyperoxia.
Finally, in a subgroup of patients even short periods of hy-
peroxia may induce or aggravate organ injury. For example 
cisplatin, one of the most widely-used chemotherapeutic 
agents against various malignancies may generate reactive 
oxygen species, which impair cellular antioxidant defence 
system, causing oxidative stress and cell injury, particularly 
in the kidney and the heart (75). In addition decreased re-
nal function due to cisplatin may also aggravate bleomycin 
pulmonary toxicity (76). Although they represent a minority 
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among surgical cases, the risk of SSI is considerably increased 
due to a compromised immune system. Should we really ex-
pose these patients to high FIO2 during general anaesthesia 
and in the postoperative period? In any case supplemental 
oxygen should be carefully considered for risk benefit ratio in 
patients with cytotoxic agents known to cause pulmonary or 
cardiac toxicity.
Obviously supplemental oxygen is indicated in hypoxic pa-
tients by improving oxygen delivery, maintaining cellular 
function and metabolism and preserving organ function. 
However it is unclear whether normoxic patients really ben-
efit from supplemental oxygen. Unless large prospective ran-
domised clinical trials clearly demonstrate an advantage of 
hyperoxia in the perioperative period - e.g. the ongoing study 
NCT01777568-Clinical Trials.gov (Supplemental oxygen 
in colorectal surgery: a quality improvement project) - the 
WHO and CDC guidelines seem to be poorly justified (9).
* * *
Göran Hedenstierna: 
The world health organization (WHO) presented guidelines 
recommending the use of hyperoxic gas (80% O2) during an-
esthesia and, if feasible, for 2-6 hours post operatively (21). 
One can argue against these guidelines, perhaps for several 
reasons, but I will limit my critical attitude to two issues.
Firstly, the scientific basis is not at all well founded. The 
guidelines are based on a meta-analysis and could be a final 
and conclusive document if there are no more studies coming 
out after the publication of the guidelines. However, studies 
on perioperative hyperoxia continue to be published that are 
at variance with the guidelines (17), and more are to come. 
We shall not accept guidelines that have weak scientific or sta-
tistical support, if any, and that are of very temporary valid-
ity, if any. The scientific basis is already more or less obsolete 
and new guidelines may be completely different. The present 
WHO guidelines are thus not at all timely, rather a comment 
in an ongoing debate. 
Secondly, the use of hyperoxic gas may initiate a number of 
events on a macroscopic as well as on a microscopic level. Mac-
roscopically, atelectasis will be more easily produced during 
anesthesia and postoperatively when breathing hyperoxic gas 
(77, 78). Thus, atelectasis is caused by absorption of alveolar 
gas, and oxygen is the gas that is absorbed the fastest since it 
is being consumed in the body. Alveolar nitrogen is hardly 
absorbed at all and acts as a scaffold, preventing collapse. Re-
ducing the nitrogen in the alveoli speeds up the lung collapse 
and by continuing the hyperoxia in the postoperative period 
makes atelectasis to last for a longer period. Atelectasis may 
be a locus of inflammation. Microscopically, the production 
or release of reactive oxygen species by using hyperoxic gas is 
most likely harmful to the patient (79). Studies in different 
experimental animals show considerable decrease in survival 
by using hyperoxic gas (80). So far few human studies have 
been conducted and they are difficult to interpret because of 
several simultaneous biological processes. However, recently 
two studies have appeared on intensive care patients, relating 
survival to arterial oxygenation. They showed increased mor-
tality in those who had high oxygen tension (PaO2) or satu-
ration (SaO2) when comparing patients with similar severity 
of disease (62) and when relating the mortality to the magni-
tude and duration of hyperoxia (49). One can always discuss 
whether the patient selection has been identical in the groups 
(62) and if a retrospective study, although on a huge material 
(close to 15000 patients), can be considered free from bias 
(49). Moreover, these results are from severely sick patients 
and not from patients undergoing scheduled surgery. Howev-
er, the results suggest rather strongly that hyperoxic gas is not 
good but more likely harmful and even deadly.
So, in summary the guidelines of using hyperoxic gas periop-
eratively is more harmful than helpful. It may even be said, 
to put it provocatively, that hyperoxia is for the doctor, not 
for the patient.
* * *
Harriet W. Hopf:
At first glance, the two largest randomized controlled trials 
that specifically evaluated the use of high inspired oxygen 
perioperatively in patients at high risk for surgical site infec-
tion Greif et al. (1), in colon surgery patients and Meyhoff et 
al. (10), in abdominal surgery patients, yielded conflicting 
results, calling into question the potential value of high-in-
spired oxygen. Greif et al. (1) demonstrated a 50% reduction 
in surgical site infection (SSI) rate (11.2% vs 5.2%, p=0.01), 
while Meyhoff et al. (10), in the PROXI trial, demonstrated 
no difference (19.1% vs. 20.1%), using effectively the same 
high-inspired oxygen protocol: 80% vs. 30% intraoperative-
ly and for the first 2 hours postoperatively. This presumes 
that the two trials investigated the same hypothesis. In re-
ality, they did not, and the outcomes are somewhat predict-
able, given the differences in study aims and design. For the 
study by Greif et al. (1), the study question could be stated: 
In patients who are managed to reduce sympathetic nervous 
system (SNS) activation and increase wound perfusion, does 
administration of high-inspired oxygen increase wound ox-
ygen tension (PwO2) and decrease SSI? For the PROXI trial, 
it could be stated: Does administration of high-inspired ox-
ygen, in the context of severely limited fluid administration, 
decrease SSI? 
Starting in the 1960s, Dr. Thomas K. Hunt and other inves-
tigators used animal, volunteer, and patient studies (81) to 
investigate the role of oxygen in wound healing. The basic 
science is clear: oxygen is required at a high partial pressure 
for wound immunity (threshold ~ 40 mmHg) (20), collagen 
deposition (threshold ~25 mmHg) (82), neovascularization 
(83), and epithilization (84). In 1997, before the widespread 
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adoption of intraoperative patient warming, Hopf et al. (14) 
demonstrated a high rate of wound hypoxia in postopera-
tive surgical patients, with SSI rate inversely proportional 
to postoperative PwO2. Animal, volunteer and patient stud-
ies demonstrated the crucial role of the SNS in controlling 
wound perfusion and PwO2
 (81) and the effectiveness of ther-
mal management (3), pain control (4), and adequate fluid 
administration (5) in maintaining PwO2. In well-perfused, 
healthy volunteers, perfusion dependent high-inspired ox-
ygen approximately doubles PwO2, from ~65 to ~100-130 
mmHg (81) Notably, Gottrup et al. (2) demonstrated in a 
dog model that hypovolemia progressively reduced both 
PwO2 and the response to 100% oxygen, with a nadir at ~20 
mmHg; after 20% blood volume removal, the response to 
oxygen was eliminated; reinfusion returned PwO2 to normal. 
A major strength of the Greif study (1) was the measurement 
of PwO2 intraoperatively and in the Post-Anesthesia Care 
Unit (PACU). PwO2 in the 80% oxygen group was approx-
imately doubled during the operation (109±43 vs. 59±15, 
p<0.001) and ~50% higher in the PACU (73±25 vs. 54±25, 
p<0.001). Mechanistically, this provides an explanation for 
the reduction in SSI. Unfortunately, no other study has 
measured PwO2 to verify that the increased inspired oxygen 
was actually delivered to the wound. The PROXI study (10) 
mandated extremely limited fluid administration, less than 
even that of so-called restricted fluid studies (85). Although 
the PROXI study did not measure PwO2, based on the PwO2 
literature, it is reasonable to assume that the lack of effect of 
high-inspired oxygen in that study stemmed, at least in part, 
from inadequate wound perfusion that reduced delivery of 
oxygen to the wound.
Thus, the first concern of an anesthesiologist should be to 
minimize SNS activation in order to optimize wound per-
fusion and oxygenation (86). Given the lack of evidence of 
harm from high-inspired oxygen (25), it is reasonable to add 
high-inspired oxygen to magnify the impact of maintaining 
adequate wound perfusion in patients at high risk for SSI 
(e.g., open abdominal surgery), or in whom SSI, though un-
common, is devastating (e.g., total joint replacement). While 
absorption atelectasis is a potential concern, it can be miti-
gated by maintaining inspired oxygen at ~80% and applying 
PEEP of 5-10 cmH2O
 (86). This is reflected in the recent 
recommendations from WHO (7) and CDC (8), which are 
reasonable and measured. Future studies should incorpo-
rate PwO2 measurements to elucidate outcomes in relation 
to whether the high-inspired oxygen effectively reached the 
wound.
* * *
Thomas K. Hunt: 
At the time I retired, I was asking for perioperative supplemental 
oxygen at every reasonable indication, and my anesthesiologist 
colleagues were willing. I would still do so now. Here is why:
1) Irrefutable science has long-since verified that wounds are 
protected from infection by innate immunity and, according-
ly, is solidly based on the availability of oxygen at almost ev-
ery step. Chemotaxis, toll receptor identification, phagocytic 
killing, angiogenesis, etc. are all effective in proportion to the 
available oxygen. There is no dissent.
2) Once hemostasis is obtained, wound tissue oxygen (PwO2) 
falls far below arterial, and is held low due largely to sym-
pathetic nervous vasoconstriction that is exceptionally active 
in the fatty tissues and fascia, which are the most common 
sites of SSI (2). Vessels in these tissues actively constrict in 
response to catecholamine release due to hypothermia, pain, 
and low blood volume (3, 4). However, these limitations can 
be mitigated. We have often witnessed a suboptimal PwO2 
rise significantly in response to increasing fluid administra-
tion, enhancing pain control, and/or warming (and upon re-
moving pheochromocytomas) while we have been measuring 
it in operative patients who were thought to be doing well by 
usual standards (5, 14, 87, 88).
3) These experiences, made it obvious to us that foundational 
clinical trials would require designs featuring warming sub-
jects to euthermia (370C), administration of generous fluids 
(estimated at least 15 ml electrolyte/kg/hr plus the usual re-
placement for losses), and patient-controlled pain manage-
ment protocols as reasonable intraoperative targets for max-
imizing PwO2 (87). Our colleagues, Kurz and Sessler (89) 
accepted these estimates in their landmark paper of 1996 in 
which they convincingly proved the value of euthermia to 
limit SSIs. Greif and Akca (1) then performed the single most 
revealing trial to date by testing 80% oxygen inhalation vs. 
30% oxygen using the Kurz protocol plus measurements of 
PwO2 in a significant number of subjects, thus demonstrat-
ing that 80% oxygen breathing under these conditions is suf-
ficient to raise PwO2 and proving that this protocol is suitable 
for clinical trials (1). In doing so, they provided substantial 
evidence that increasing PwO2 will reduce the frequency of 
SSIs. Belda, using a similar protocol, found the same result, 
but did not measure PwO2 (16). These events reignited tra-
ditional disbelief that I had encountered when I showed that 
increasing arterial PO2 could actually increase interstitial PO2 
without need for an increase in hemoglobin and also a reflex-
ive and exaggerated fear of oxygen toxicity (90). 
PROXI in Denmark (10) then performed a negative trial 
featuring 1400 subjects, fluid restriction, and loose thermal 
control without even once measuring PwO2 and seemed ea-
ger to seize on a minor break in the Greif trial to disqualify 
their analysis (25). PROXI has subsequently sought evidence 
of harm in that trial, but has failed to find it. Furthermore, 
PROXI has apparently never measured a wound PO2 (PwO2)–
although some of the investigators were trained on how to-, 
and are, therefore, unqualified to make any judgment with 
regard to SSI, because they have provided no evidence that 
their protocol sufficed to increase oxygen in the wound in 
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a significant number of subjects as would have better suited 
their contrarian position.
4) Whereas the more than fifteen published “trials” fall nicely 
into two groups: those that held essentially to the Greif-Akca 
protocol and report significant reductions of SSI and the re-
mainder that did not and found no effect.
5) My personal conclusion is: Perioperative hyperoxia can re-
duce SSI if conditions are adequate. Questions remain. Time, 
I suspect, will tell.
* * *
Motaz Qadan:
This is a topic that has continued to fuel a debate spanning 2 
decades. The following commentary represents my personal 
opinion. I believe that the question at hand has been compre-
hensively addressed but not definitively answered, due to the 
large body of conflicting data. The reason for the discrepancy in 
outcomes exists due to significant heterogeneity in studies that 
have examined the role of supplemental oxygen, unpredictabil-
ity of outcomes among patients enrolled (no applicable airline 
analogies), and implementation of arbitrary, or arguably flawed, 
statistical principles that have served to fuel the controversy.
As scientists examining the role of supplemental oxygen, one 
could argue that we have failed medical practice in our lack of 
cohesiveness and consensus on this topic. While the applica-
tion of scientific rigor and debate is encouraged, poor adher-
ence to uniform trial design has resulted in undecipherable 
outcomes, and should serve as the ultimate learning lesson for 
the medical community.
In the first study on the topic, Greif and colleagues examined 
the role of supplemental oxygen in a well-designed, rigor-
ously implemented, meticulously analyzed, and well-written 
randomized-controlled trial that established benefit from the 
administration of 80% oxygen to 250 patients, compared 
with 250 patients who did not receive supplemental oxygen 
(30% oxygen) (1). However, as is sometimes the case (more 
often with negative trials), results were not broadly accepted. 
This led to the design and implementation, followed by, argu-
ably, the inappropriate discontinuation of the Pryor study, 
which became the fulcrum for rejection of the supplemental 
oxygen theory (91). Based on the results of this incomplete 
study alone, the role of supplemental oxygen became heavily 
disputed, despite all additional level I and meta-analyzed data 
confirming Greif ’s findings (92). 
Eventually, the Meyhoff PROXI trial followed, 9 years after 
the Greif study, and showed no discernible difference be-
tween the 80% and 30% oxygen arms on surgical site infec-
tion rates (10). Unfortunately, several spin-off publications 
followed from the same data set in the form of post-hoc anal-
yses in attempts to answer questions for which the original 
trial was not designed. Disappointingly, scathing findings 
regarding the role of supplemental oxygen were reported, al-
though some of these have since been, fortunately, debunked 
(e.g. mortality associated with supplemental oxygen among 
cancer patients) (42, 43). 
In attempting to define the role of supplemental oxygen on 
surgical site infection, I have previously stated that there are 
more opinions, editorials, and commentaries on this topic 
than there are actual data! Nonetheless, it is my personal be-
lief that (protective) oxygen sinks exist in the human body, 
such as endothelial cells, which modify oxygen utilization 
and subsequent transmission to end-organs and capillaries, 
as eloquently described by Tsai et al. (93). As such, ‘excess’ 
inspired oxygen may not be fully transmitted to capillaries 
at the wound, for example. Therefore, the benefit from sup-
plemental oxygen may be smaller than anticipated. However, 
in certain procedures, such as colorectal surgery, anaerobic 
organisms prevail. As such, even a small increase in wound 
oxygen tension may result in benefit, which has indeed been 
confirmed among patients undergoing colorectal surgery. In 
addition, basic scientific data exist to support enhancement 
of innate immunologic mechanisms associated with the use 
of supplemental oxygen (20, 56). 
At this time, it should be noted that data support that admin-
istration of supplemental oxygen to anesthetized patients is 
safe in the acute perioperative period (88). Furthermore, the 
liberal use of oxygen routinely occurs during surgery. Oxygen 
is also cheap, widely available, and administration is not sup-
ported by industry or associated with any financial incentive. 
Above all, benefit from supplemental administration appears 
to be logical in principle.
Therefore, I believe that supplemental oxygen administration 
is justified, despite the extensive controversy that exists in the 
literature today. I am uncertain as to how this debate can be 
more definitively concluded.
* * *
Daniel I. Sessler: 
Surgical site infections remain an important cause of patient 
morbidity and mortality. All wounds become contaminated, 
and whether contamination progresses to clinical infection 
is determined by antibiotic administration and host defense. 
The most important defense against bacterial infection is ox-
idative killing by neutrophils. The process depends on mo-
lecular oxygen and the reaction rate depends on tissue oxygen 
over the entire clinical range. The easiest way to increase tis-
sue oxygen is to provide supplemental inspired oxygen which 
increases tissue oxygen from about 50 mmHg to about 100 
mmHg. (1) The increase is potentially clinically important 
because infections are common at the lower partial pressure 
and rare at the higher one (14).
Even a few minutes of 100% inspired oxygen, as used during 
induction of nearly every general anesthetic, causes atelecta-
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sis (94) which can be reversed with a recruitment maneuver 
(95) or positive end-expiratory pressure (98). However, 80% 
inspired oxygen does not cause atelectasis (88) and, despite 
an initial report, (42) does not increase long-term mortality. 
(43) Supplemental perioperative oxygen thus appears to be 
safe, although harm has been demonstrated in other contexts. 
But lack of harm does not justify recommendations for use. 
In recent months, both the World Health Organization (21) 
and the United States Center for Disease Control (8) have 
issued guidelines recommending that adults having general 
anaesthesia should be given 80% inspired oxygen intraoper-
atively and, when feasible, also for 2-6 hours thereafter to 
reduce the risk of surgical site infection. These recommen-
dations fail to consider divergent results of available trials, 
that recent large trials have uniformly failed to demonstrate 
benefit, (10, 17) and that a meta-analysis of available trials 
shows that supplemental oxygen does not significantly reduce 
the risk of surgical site infection (9). The results of a large trial 
will soon provide definitive evidence of whether supplemen-
tal oxygen reduces surgical site infection (NCT01777568). 
Curiously, the World Health Organization recommendation 
specifically includes regional anesthesia, although not a sin-
gle study of supplemental oxygen during regional anesthesia 
identified any benefit (97-100). 
References
1. Greif R, Akça O, Horn E-P, Kurz A, Sessler DI, Outcomes Research™ 
Group. Supplemental perioperative oxygen to reduce the incidence of 
surgical wound infection. N Engl J Med 2000; 342: 161-7. [CrossRef]
2. Gottrup F, Firmin R, Rabkin J, Halliday BJ, Hunt TK. Directly 
measured tissue oxygen tension and arterial oxygen tension assess 
tissue perfusion. Crit Care Med 1987; 15: 1030-6. [CrossRef]
3. Sheffield CW, Sessler DI, Hopf HW, Schroeder M, Moayeri A, 
Hunt TK, et al. Centrally and locally mediated thermoregulatory 
responses alter subcutaneous oxygen tension. Wound Repair Re-
gen 1996; 4: 339-45. [CrossRef]
4. Akça O, Melischek M, Scheck T, Hellwagner K, Arkiliç C, Kurz 
A, et al. Postoperative pain and subcutaneous oxygen tension. 
Lancet 1999; 354: 41-2. [CrossRef]
5. Arkilic CF, Taguchi A, Sharma N, Ratnaraj J, Sessler DI, Read TE, 
et al. Supplemental perioperative fluid administration increases tis-
sue oxygen pressure. Surgery 2003; 133: 49-55. [CrossRef]
6. Akça O, Doufas A, Morioka N, Iscoe S, Fisher J, Sessler D. Hy-
percapnia Improves Tissue Oxygenation. Anesthesiology 2002; 
97: 801-6. [CrossRef]
7. Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de 
Vries F, et al. New WHO recommendations on intraoperative 
and postoperative measures for surgical site infection prevention: 
an evidence-based global perspective.  Lancet Infect Dis 2016; 
16: e288-e303. 
8. Berrios-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone 
EC, Kelz RR, et al. Centers for Disease Control and Prevention 
Guideline for the Prevention of Surgical Site Infection. JAMA 
Surg 2017 May 3. doi: 10.1001/jamasurg.2017.0904. [Epub 
ahead of print] [CrossRef]
9. Volk T, Peters J, Sessler DI. The WHO recommendation for 80% 
perioperative oxygen is poorly justified. Anaesthesist 2017; 66: 
227-9. [CrossRef]
10. Meyhoff CS, Wetterslev J, Jorgensen LN, Henneberg SW, Hog-
dall C, Lundvall L, et al. Effect of high perioperative oxygen frac-
tion on surgical site infection and pulmonary complications after 
abdominal surgery: the PROXI randomized clinical trial. JAMA 
2009; 302: 1543-50. [CrossRef]
11. Hunt TK. A New Method of Determining Tissue Oxygen Ten-
sion. Lancet 1964; 2: 1370-1. [CrossRef]
12. Hunt TK, Dunphy JE. Effects of increasing oxygen supply to 
healing wounds. Br J Surg 1969; 56: 705. 
13. Hunt TK, Linsey M, Sonne M, Jawetz E. Oxygen tension and 
wound infection. Surg Forum 1972; 23: 47-9. 
14. Hopf HW, Hunt TK, West JM, Blomquist P, Goodson WH, 3rd, 
Jensen JA, et al. Wound tissue oxygen tension predicts the risk of 
wound infection in surgical patients. Arch Surg 1997; 132: 997-
1004; discussion 1005.
15. Akca O, Kurz A, Fleischmann E, Buggy D, Herbst F, Stocchi L, 
et al. Hypercapnia and surgical site infection: a randomized trial. 
Br J Anaesth 2013; 111: 759-67. [CrossRef]
16. Belda FJ, Aguilera L, Garcia de la Asuncion J, Alberti J, Vicente 
R, Ferrandiz L, et al. Supplemental perioperative oxygen and the 
risk of surgical wound infection: a randomized controlled trial. 
JAMA 2005; 294: 2035-42. [CrossRef]
17. Kurz A, Fleischmann E, Sessler DI, Buggy DJ, Apfel C, Akca 
O, et al. Effects of supplemental oxygen and dexamethasone on 
surgical site infection: a factorial randomized trialdouble dagger. 
Br J Anaesth 2015; 115: 434-43. [CrossRef]
18. Güldner A, Kiss T, Serpa Neto A, Hemmes SN, Canet J, Spieth 
PM, et al. Intraoperative Protective Mechanical Ventilation for 
Prevention of Postoperative Pulmonary Complications A Com-
prehensive Review of the Role of Tidal Volume, Positive End-ex-
piratory Pressure, and Lung Recruitment Maneuvers. Anesthesi-
ology 2015; 123: 692-713. [CrossRef]
19. Kroell W, Metzler H, Struber G, Wegscheider T, Gombotz 
H, Hiesmayr M, et al. The LAS VEGAS investigators for the 
PROVE Network, the Clinical Trial Network of the European 
Society of Anaesthesiology. Epidemiology, practice of ventilation 
and outcome for patients at increased risk of postoperative pul-
monary complications: An observational study in 29 countries. 
Eur J Anaesthesiol 2017; 34: 492-507. [CrossRef]
20. Allen DB, Maguire JJ, Mahdavian M, Wicke C, Marcocci L, Scheuen-
stuhl H, et al. Wound hypoxia and acidosis limit neutrophil bacterial 
killing mechanisms. Arch Surg 1997; 132: 991-6. [CrossRef]
21. Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de 
Vries F, et al. WHO Guidelines Development Group. New 
WHO recommendations on intraoperative and postoperative 
measures for surgical site infection prevention: an evidence-based 
global perspective. Lancet Infect Dis 2016; 16: e288-e303. 
22. Ball L, Lumb AB, Pelosi P. Intraoperative fraction of inspired ox-
ygen: bringing back the focus on patient outcome. Br J Anaesth 
2017; 119: 16-8. [CrossRef]
23. Hedenstierna G, Perchiazzi G, Meyhoff CS, Larsson A. Who 
Can Make Sense of the WHO Guidelines to Prevent Surgical 
Site Infection? Anesthesiology 2017; 126: 771-3. 
24. Myles PS, Leslie K, Chan MTV, Forbes A, Paech MJ, Peyton P, et al. 
Avoidance of Nitrous Oxide for Patients Undergoing Major Surgery: 
A Randomized Controlled Trial. Anesthesiology 2007; 107: 221-31. 
[CrossRef]
25. Wetterslev J, Meyhoff CS, Jørgensen LN, Gluud C, Lindschou 
J, Rasmussen LS. The effects of high perioperative inspiratory 
oxygen fraction for adult surgical patients. Cochrane Database 
Syst Rev 2015; (6): CD008884.
26. De Jong A, Futier E, Millot A, Coisel Y, Jung B, Chanques G, et al. 
How to preoxygenate in operative room: healthy subjects and situa-
tions ‘at risk’. Ann Fr Anesth Reanim 2014; 33: 457-61. [CrossRef]
Turk J Anaesthesiol Reanim 2017; 45: 181-92
190
27. Ball L, Bos LD, Pelosi P. High-flow nasal cannula in the postop-
erative period: is positive pressure the phantom of the OPERA 
trial? Intensive Care Med 2017; 43: 119-21. 
28. Ferrando C, Romero C, Tusman G, Suarez-Sipmann F, Canet 
J, Dosdá R, et al. The accuracy of postoperative, non-invasive 
Air-Test to diagnose atelectasis in healthy patients after surgery: a 
prospective, diagnostic pilot study. BMJ Open 2017; 7: e015560. 
29. Nimmagadda U, Salem MR, Crystal GJ. Preoxygenation: Physiologic 
Basis, Benefits, and Potential Risks. Anesth Analg 2017; 124: 507-17. 
[CrossRef]
30. Ang KS, Green A, Ramaswamy KK, Frerk C. Preoxygenation using 
the Optiflow™system. Br J Anaesth 2017; 118: 463-4. [CrossRef]
31. Ricard JD. Hazards of intubation in the ICU: role of nasal high 
flow oxygen therapy for preoxygenation and apneic oxygenation 
to prevent desaturation. Minerva Anestesiol 2016; 82: 1098-106.
32. Slinger PD. Is There Anything New About Preoxygenation? 
Duh, Yeah! Anesth Analg 2017; 124: 388-9.
33. Hovaguimian F, Lysakowski C, Elia N, Tramèr MR. Effect of 
intraoperative high inspired oxygen fraction on surgical site 
infection, postoperative nausea and vomiting, and pulmonary 
function: systematic review and meta-analysis of randomized 
controlled trials. Anesthesiology 2013; 119: 303-16. [CrossRef]
34. García de la Asunción J, Belda FJ, Greif R, Barber G, Viña J, Sastre 
J. Inspired supplemental oxygen reduces markers of oxidative stress 
during elective colon surgery. Br J Surg 2007; 94: 475-7. [CrossRef]
35. García-de-la-Asunción J, Barber G, Rus D, Perez-Griera J, Belda 
FJ, Martí F, et al. Hyperoxia during colon surgery is associated 
with a reduction of xanthine oxidase activity and oxidative stress 
in colonic mucosa. Redox Rep 2011; 16: 121-8. [CrossRef]
36. Wang H, Hong S, Liu Y, Duan Y, Yin H. High inspired oxygen 
versus low inspired oxygen for reducing surgical site infection: a 
meta-analysis. Int Wound J 2017; 14: 46-52. [CrossRef]
37. Yang W, Liu Y, Zhang Y, Zhao QH, He SF. Effect of intra-op-
erative high inspired oxygen fraction on surgical site infection: 
a meta-analysis of randomized controlled trials. J Hosp Infect 
2016; 93: 329-38. [CrossRef]
38. Vallabha T, Karjol U, Kalyanappagol V, Sindgikar V, Nidoni R, 
Biradar H, et al. Rational Hyperoxia in the Perioperative Period: 
a Safe and Effective Tool in the Reduction of SSI. Indian J Surg 
2016; 78: 27-31. [CrossRef]
39. Ferrando C, Soro M, Belda FJ. Protection strategies during car-
diopulmonary bypass: ventilation, anesthetics and oxygen. Curr 
Opin Anaesthesiol 2015; 28: 73-80. [CrossRef]
40. Smit B, Smulders YM, de Waard MC, Boer C, Vonk AB, Veer-
hoek D, et al. Moderate hyperoxic versus near-physiological ox-
ygen targets during and after coronary artery bypass surgery: a 
randomised controlled trial. Crit Care 2016; 20: 55. [CrossRef]
41. Sutton AD, Bailey M, Bellomo R, Eastwood GM, Pilcher DV. 
The association between early arterial oxygenation in the ICU 
and mortality following cardiac surgery. Anaesth Intensive Care 
2014; 42: 730-5.
42. Meyhoff CS, Jorgensen LN, Wetterslev J, Christensen KB, Ras-
mussen LS; PROXI Trial Group. Increased long-term mortality 
after a high perioperative inspiratory oxygen fraction during ab-
dominal surgery: follow-up of a randomized clinical trial. Anesth 
Analg 2012; 115: 849-54. [CrossRef]
43. Podolyak A, Sessler DI, Reiterer C, Fleischmann E, Akça O, 
Mascha EJ, et al. Perioperative Supplemental Oxygen Does Not 
Worsen Long-Term Mortality of Colorectal Surgery Patients. 
Anesth Analg 2016; 122: 1907-11. [CrossRef]
44. White GC. Basic Clinical Lab Competencies for Respiratory 
Care. 4th ed. New York: Delmar Cengage Learning; 2002.p.230. 
45. Bitterman N. CNS oxygen toxicity. Undersea Hyperb Med 
2004; 31: 63-72.
46. Clark JM, Lambertsen CJ. Pulmonary oxygen toxicity: a review. 
Pharmacol Rev 1971; 23: 37-133.
47. Sjoberg F, Singer M. The medical use of oxygen: a time for critical 
reappraisal. J Intern Med 2013; 274: 505-28. [CrossRef]
48. Jindal SK, Agarwal R. Long-term oxygen therapy. Expert Rev 
Respir Med 2012; 6: 639-49. [CrossRef]
49. Helmerhorst HJF, Arts DL, Schultz MJ, van der Voort PHJ, 
Abu-Hanna A, de Jonge E, et al. Metrics of Arterial Hyperoxia 
and Associated Outcomes in Critical Care. Crit Care Med 2017; 
45: 187-95. [CrossRef]
50. Dussault C, Gontier E, Verret C, Soret M, Boussuges A, Heden-
stierna G, et al. Hyperoxia and hypergravity are independent risk 
factors of atelectasis in healthy sitting humans: a pulmonary ul-
trasound and SPECT/CT study. J Appl Physiol (1985) 2016; 
121: 66-77. [CrossRef]
51. Sommer N, Dietrich A, Schermuly RT, Ghofrani HA, Gudermann 
T, Schulz R, et al. Regulation of hypoxic pulmonary vasoconstriction: 
basic mechanisms. Eur Respir J 2008; 32: 1639-51. [CrossRef]
52. Naeije R, Brimioulle S. Physiology in medicine: importance of hypoxic 
pulmonary vasoconstriction in maintaining arterial oxygenation during 
acute respiratory failure. Crit Care 2001; 5: 67-71. [CrossRef]
53. Nash G, Blennerhassett JB, Pontoppidan H. Pulmonary lesions 
associated with oxygen therapy and artifical ventilation. N Engl J 
Med 1967; 276: 368-74. [CrossRef]
54. Sinclair SE, Altemeier WA, Matute-Bello G, Chi EY. Augmented 
lung injury due to interaction between hyperoxia and mechanical 
ventilation. Crit Care Med 2004; 32: 2496-501. [CrossRef]
55. Duling BR. Microvascular responses to alterations in oxygen ten-
sion. Circ Res 1972; 31: 481-9. [CrossRef]
56. Qadan M, Battista C, Gardner SA, Anderson G, Akca O, Polk HCJ. 
Oxygen and surgical site infection: a study of underlying immuno-
logic mechanisms. Anesthesiology 2010; 113: 369-77. [CrossRef]
57. O'Reilly PJ, Hickman-Davis JM, Davis IC, Matalon S. Hyperoxia 
impairs antibacterial function of macrophages through effects on 
actin. Am J Respir Cell Mol Biol 2003; 28: 443-50. [CrossRef]
58. Helmerhorst HJF, Schouten LRA, Wagenaar GTM, Juffermans 
NP, Roelofs JJTH, Schultz MJ, et al. Hyperoxia provokes a time- 
and dose-dependent inflammatory response in mechanically ven-
tilated mice, irrespective of tidal volumes. Intensive Care Med 
Exp 2017; 5: 27. [CrossRef]
59. Vincent JL, Taccone FS, He X. Harmful Effects of Hyperoxia in 
Postcardiac Arrest, Sepsis, Traumatic Brain Injury, or Stroke: The 
Importance of Individualized Oxygen Therapy in Critically Ill 
Patients. Can Respir J 2017; 2017: 2834956. [CrossRef]
60. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE 
et al. Air Versus Oxygen in ST-Segment-Elevation Myocardial 
Infarction. Circulation 2015; 131: 2143-50. [CrossRef]
61. Eastwood GM, Young PJ, Bellomo R. The impact of oxygen and 
carbon dioxide management on outcome after cardiac arrest. 
Curr Opin Crit Care 2014; 20: 266-72. [CrossRef]
62. Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, et 
al. Effect of Conservative vs Conventional Oxygen Therapy on Mor-
tality Among Patients in an Intensive Care Unit: The Oxygen-ICU 
Randomized Clinical Trial. JAMA 2016; 316: 1583-9. [CrossRef]
63. Damiani E, Adrario E, Girardis M, Romano R, Pelaia P, Singer M, et 
al. Arterial hyperoxia and mortality in critically ill patients: a system-
atic review and meta-analysis. Crit Care 2014; 18: 711. [CrossRef]
64. Fonnes S, Gögenur I, Søndergaard ES, Siersma VD, Jorgensen LN, 
Wetterslev J, et al. Perioperative hyperoxia - Long-term impact on car-
diovascular complications after abdominal surgery, a post hoc analysis 
of the PROXI trial. Int J Cardiol 2016; 215: 238-43. [CrossRef]
65. Meyhoff CS, Jorgensen LN, Wetterslev J, Siersma VD, Rasmus-
sen LS, PROXI Trial Group. Risk of new or recurrent cancer after 
Akca et al. WHO Needs High FIO2?
191
a high perioperative inspiratory oxygen fraction during abdomi-
nal surgery. Br J Anaesth 2014; 113(Suppl 1): i74-i81. 
66. Milone SD, Newton GE, Parker JD. Hemodynamic and bio-
chemical effects of 100% oxygen breathing in humans. Can J 
Physiol Pharmacol 1999; 77: 124-30. [CrossRef]
67. Lodato RF. Decreased O2 consumption and cardiac output 
during normobaric hyperoxia in conscious dogs. J Appl Physiol 
(1985) 1989; 67: 1551-9.
68. Farquhar H, Weatherall M, Wijesinghe M, Perrin K, Ranchord A, 
Simmonds M, et al. Systematic review of studies of the effect of 
hyperoxia on coronary blood flow. Am Heart J 2009; 158: 371-7. 
[CrossRef]
69. McNulty PH, King N, Scott S, Hartman G, McCann J, Kozak 
M, et al. Effects of supplemental oxygen administration on cor-
onary blood flow in patients undergoing cardiac catheterization. 
Am J Physiol Heart Circ Physiol 2005; 288: H1057-62.
70. Asfar P, Singer M, Radermacher P. Understanding the benefits 
and harms of oxygen therapy: response to comments by Akca. 
Intensive Care Med 2015; 41: 1875. [CrossRef]
71. Sivakumar H, Peyton PJ. Poor agreement in significant findings 
between meta-analyses and subsequent large randomized trials in 
perioperative medicine. Br J Anaesth 2016; 117: 431-41. [CrossRef]
72. Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S, et 
al. Oxygen therapy in acute coronary syndrome: are the benefits 
worth the risk? Eur Heart J 2013; 34: 1630-5. 
73. Lopez MG, Pandharipande P, Morse J, Shotwell MS, Milne GL, 
Pretorius M, et al.  Intraoperative cerebral oxygenation, oxidative 
injury, and delirium following cardiac surgery. Free Radic Biol 
Med 2017; 103: 192-8. [CrossRef]
74. Kilgannon JH, Jones AE, Shapiro NI, Angelos MG, Milcarek B, 
Hunter K, et al. Emergency Medicine Shock Research Network 
(EMShockNet) Investigators. Association between arterial hyper-
oxia following resuscitation from cardiac arrest and in-hospital 
mortality. JAMA 2010; 303: 2165-71. [CrossRef]
75. Dugbartey GJ, Peppone LJ, de Graaf IA. An integrative view of 
cisplatin-induced renal and cardiac toxicities: Molecular mech-
anisms, current treatment challenges and potential protective 
measures. Toxicology 2016; 371: 58-66. [CrossRef]
76. Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. 
Enhanced effects of bleomycin on pulmonary function distur-
bances in patients with decreased renal function due to cisplatin. 
Eur J Cancer 1996; 32A: 550-2.
77. Hedenstierna G, Rothen HU. Respiratory function during anesthesia: 
effects on gas exchange. Compr Physiol 2012; 2: 69-96. [CrossRef]
78. Edmark L, Auner U, Enlund M, Ostberg E, Hedenstierna G. Oxy-
gen concentration and characteristics of progressive atelectasis forma-
tion during anaesthesia. Acta Anaesthesiol Scand 2011; 55: 75-81. 
[CrossRef]
79. Pagano A, Barazzone-Argiroffo C. Alveolar cell death in hyperoxia-in-
duced lung injury. Ann N Y Acad Sci 2003; 1010: 405-16. [CrossRef]
80. Matute-Bello G, Frevert CW, Martin TR. Animal models of 
acute lung injury. Am J Physiol Lung Cell Mol Physiol 2008; 
295: L379-99.
81. Hopf HW. Development of subcutaneous wound oxygen mea-
surement in humans: contributions of Thomas K Hunt, MD. 
Wound Repair Regen 2003; 11: 424-30. [CrossRef]
82. Jonsson K, Jensen JA, Goodson WH 3rd, Scheuenstuhl H, West 
J, Hopf HW, et al. Tissue oxygenation, anemia, and perfusion in 
relation to wound healing in surgical patients. Ann Surg 1991; 
214: 605-13. [CrossRef]
83. Hopf HW, Gibson JJ, Angeles AP, Constant JS, Feng JJ, Rollins 
MD, et al. Hyperoxia and angiogenesis. Wound Repair Regen 
2005; 13: 558-64. [CrossRef]
84. Medawar PS. The behavior of mammalian skin epithelium under 
strictly anaerobic conditions. Q J Microsc Sci 1947; 88: 27-37.
85. Brandstrup B, Tønnesen H, Beier-Holgersen R. Effects of intrave-
nous fluid restriction on postoperative complications: comparison 
of two perioperative fluid regimens: a randomized assessor-blinded 
multicenter trial. Ann Surg 2003; 238: 641-8. [CrossRef]
86. Hopf HW, Cochran A, Ueno C, Morrissey C. Inflammation, 
Wound Healing, and Infection. In: Barash P, Cullen B, Stoelting 
R, Cahalan M, Stock C, editors. Clinical Anesthesia 8th ed. Phil-
adelphia: Lippincott Williams & Wilkins; 2017.p.183-203.
87. Hopf HW, Viele M, Watson JJ, Feiner J, Weiskopf R, Hunt TK, 
et al. Subcutaneous perfusion and oxygen during acute severe 
isovolemic hemodilution in healthy volunteers. Arch Surg 2000; 
135: 1443-9. [CrossRef]
88. Akca O, Podolsky A, Eisenhuber E, Panzer O, Hetz H, Lampl K, 
et al. Comparable postoperative pulmonary atelectasis in patients 
given 30% or 80% oxygen during and 2 hours after colon resec-
tion. Anesthesiology 1999; 91: 991-8. [CrossRef]
89. Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia 
to reduce the incidence of surgical-wound infection and short-
en hospitalization. Study of Wound Infection and Temperature 
Group. N Engl J Med 1996; 334: 1209-15. [CrossRef]
90. Feiner JR, Finlay-Morreale HE, Toy P, Lieberman JA, Viele MK, 
Hopf HW, et al. High oxygen partial pressure decreases ane-
mia-induced heart rate increase equivalent to transfusion. Anes-
thesiology 2011; 115: 492-8. [CrossRef]
91. Pryor KO, Fahey TJ, 3rd, Lien CA, Goldstein PA. Surgical site 
infection and the routine use of perioperative hyperoxia in a gen-
eral surgical population: a randomized controlled trial. JAMA 
2004; 291: 79-87. [CrossRef]
92. Qadan M, Akca O, Mahid SS, Hornung CA, Polk HC, Jr. 
Perioperative supplemental oxygen therapy and surgical site in-
fection: a meta-analysis of randomized controlled trials. Arch 
Surg 2009; 144: 359-66; discussion 66-7.
93. Tsai AG, Johnson PC, Intaglietta M. Oxygen gradients in the 
microcirculation. Physiol Rev 2003; 83: 933-63. [CrossRef]
94. Edmark L, Kostova-Aherdan K, Enlund M, Hedenstierna G. 
Optimal oxygen concentration during induction of general an-
esthesia. Anesthesiology 2003; 98: 28-33. [CrossRef]
95. Rothen HU, Sporre B, Engberg G, Wegenius G, Hedenstierna 
G. Reexpansion of atelectasis during general anaesthesia may 
have a prolonged effect. Acta Anaesthesiol Scand 1995; 39: 118-
25. [CrossRef]
96. Rusca M, Proietti S, Schnyder P, Frascarolo P, Hedenstierna G, Spahn 
DR, et al. Prevention of atelectasis formation during induction of 
general anesthesia. Anesth Analg 2003; 97: 1835-9. [CrossRef]
97. Gardella C, Goltra LB, Laschansky E, Drolette L, Magaret A, 
Chadwick HS, et al. High-concentration supplemental perioper-
ative oxygen to reduce the incidence of postcesarean surgical site 
infection: a randomized controlled trial. Obstet Gynecol 2008; 
112: 545-52. [CrossRef]
98. Scifres CM, Leighton BL, Fogertey PJ, Macones GA, Stamilio 
DM. Supplemental oxygen for the prevention of postcesarean 
infectious morbidity: a randomized controlled trial. Am J Obstet 
Gynecol 2011; 205: 267 e1-9.
99. Duggal N, Poddatoori V, Noroozkhani S, Siddik-Ahmad RI, 
Caughey AB. Perioperative oxygen supplementation and surgical 
site infection after cesarean delivery: a randomized trial. Obstet 
Gynecol 2013; 122: 79-84. [CrossRef]
100. Williams NL, Glover MM, Crisp C, Acton AL, McKenna DS. 
Randomized controlled trial of the effect of 30% versus 80% 
fraction of inspired oxygen on cesarean delivery surgical site in-
fection. Am J Perinatol 2013; 30: 781-6. [CrossRef]
Turk J Anaesthesiol Reanim 2017; 45: 181-92
192
